Ferring Announces Ground-Breaking and Inclusive Family Building Benefits Package for All Its Employees Globally
14.7.2022 08:00:00 EEST | Business Wire | Press release
Ferring Pharmaceuticals is committed to building families of every shape and size. As part of this commitment, Ferring has announced the introduction of a new global family building benefits package for its employees. The holistic three-tier support model provides family building financial benefits, a ground-breaking 26-week global minimum standard of equal paid parental leave for both birthing and non-birthing parents as well as increased awareness and support at work.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220707005467/en/
(Infographic: Business Wire)
The comprehensive package recognises the complexities of building a family and aims to enable different family building options by removing the financial barriers and providing access to quality care. Unlimited financial assistance is provided within the scope of its providers’ services.
Ferring’s support package provides equal opportunities to becoming a parent regardless of medical need, personal circumstances or family structure. This means providing the financial support required to access fertility treatments, surrogacy programmes, adoption, egg freezing, counselling and related services. Additionally, to ensure employees feel supported during the process of their family building journey, paid leave is available for fertility treatment and adoption procedures.
Building on the long-standing fertility benefits package offered to its US-based employees via its provider, Progyny, Ferring has now engaged Carrot, to support its employees in the rest of the world.
Infertility is a significant clinical issue, estimated to affect 1 in 6 heterosexual couples globally.1,2 Research has found that the negative impacts of infertility are profound and a clear gap exists between the number of people who experience mental health issues due to infertility and the number seeking help to address these mental health issues.3 Underlying the practical support provided by the new package will be support for employees’ emotional wellbeing, with four weeks paid leave provided for miscarriage for example, and counselling services offered to all employees from the outset of their fertility journey.
“At Ferring we commit to advocating for everyone’s right to build a family, no matter who you are, where you live or who you love. The new family building support package ensures a global standard for support irrespective of location, role or family circumstances. It makes no assumptions about gender, sexual orientation or relationship status, or about parental roles or responsibilities in the early stages of childcare,” said Christelle Beneteau, Executive Committee member and Chief Human Resources Officer at Ferring Pharmaceuticals.
Christelle added: “As we strive to lead by example in becoming a fertility and family friendly employer, I’m immensely proud of this world-leading, comprehensive and inclusive package. All of our employees collectively contribute to advancing our mission to build families and help people live better lives. We want to do everything we can to support them in their own family building journeys, removing barriers and provide an environment in which they are empowered to focus on their families at this important time.”
As a leading global healthcare company in reproductive medicine and maternal health, Ferring aims to advance its #ProjectFamily Commitment by creating a fertility and family friendly experience at work and increase awareness of the experiences of family building journeys and to foster support, respect and understanding in all its workplaces. Through training, awareness events and open dialogue, Ferring will ensure that its new family building support package goes further than financial assistance or leave policies and creates a world leading family and fertility friendly workplace.
About Ferring Pharmaceuticals
Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group committed to helping people around the world build families and live better lives. Headquartered in Saint-Prex, Switzerland, Ferring is a leader in reproductive medicine and maternal health, and in specialty areas within gastroenterology and urology. Ferring has been developing treatments for mothers and babies for over 50 years and has a portfolio covering treatments from conception to birth. Founded in 1950, privately-owned Ferring now employs around 6,000 people worldwide, has its own operating subsidiaries in more than 50 countries, and markets its products in 110 countries.
Learn more at www.ferring.com, or connect with us on Twitter, Facebook, Instagram, LinkedIn and YouTube.
Note: The availability of financial support and access to some benefits is subject to compliance with local laws.
# # #
References:
1 European Society of Human Reproduction and Embryology, ART Factsheet 2018. Available at: https://www.eshre.eu/Press-Room/Resources. Last accessed March 2022.
2 World Health Organization. Infertility. Available https://www.who.int/health-topics/infertility#tab=tab_1. Last accessed March 2022.
3 Boivin J et al. Tailored support may be required to reduce the impact of the infertility journey on mental health, relationships and daily lives of infertile patients and partners to infertile patients. Reproductive Biomedicine online. March 2022. DOI: https://doi.org/10.1016/j.rbmo.2022.01.015
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220707005467/en/
Contact information
For more information, please contact
Yasmin Gharib
Account Director, Syneos Health Communications PR Europe
+44 (0)7788 663 999 (mobile)
yasmin.gharib@syneoshealth.com
A
dam Alexander
Senior Account Executive, Syneos Health Communications PR Europe
+44 785 469 4245 (mobile)
adam.alexander@syneoshealth.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Beacon Acquires Haize Labs to Power AI for the Real Economy17.9.2026 17:30:00 EEST | Press release
Beacon Software (Beacon), the first centralized AI holding company, today announced that it has acquired Haize Labs, an AI reliability company that tests and safeguards AI agents for real-world deployment. The Haize Labs team will join Beacon to form its Applied AI Research Group, with co-founder and CEO Leonard Tang joining as VP of AI Research to lead the AI operating system that is deployed across Beacon’s companies. Beacon believes that the fastest way to bring AI to the traditional economy is through the software businesses that essential industries already use and trust, equipping them with AI infrastructure. Beacon acquires these businesses for long-term growth and connects them to a centralized AI operating system that compounds with each additional acquisition and industry. The addition of the Haize Labs team will strengthen this centralized technology platform, which provides shared engineering, AI, product and go-to-market capabilities to Beacon’s portfolio of 45 software co
TIMELAB Develops OEM/ODM Hair Straightener Reaching 200°C at All Three Measured Points in 15 Seconds17.9.2026 17:00:00 EEST | Press release
TIMELAB Co., Ltd., a Japanese beauty-appliance OEM/ODM provider, has developed a hair straightener for OEM/ODM customization for international hair care brands and professional markets. In testing at 230 V with a 260°C setting, all three measured plate locations reached at least 200°C after 15 seconds. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260914187865/en/ Three-Point Plate Testing A European-market development unit with a maximum setting of 260°C was tested at 230 V. Fifteen seconds after power-on, readings at the front, center and rear were 212.5°C, 227.5°C and 200.0°C, respectively. From around 60 seconds onward, temperature differences among the three points narrowed, indicating a stable trend. Precision Temperature Control An NTC sensor inside the metal ceramic heater (MCH) detects temperature. A microcontroller (MCU) reads the signal and adjusts heater output. Upper and lower MCH heaters are controlled indepen
Earnix Brings Agentic AI to the Decisions That Drive Insurance Performance17.9.2026 16:09:00 EEST | Press release
Earnix today announced the introduction of Agent Hub, a curated catalog of insurance-specific AI agents and apps within Earnix AIOS — the AI Orchestration System powering Earnix’s pricing and rating, underwriting, and customer engagement solutions. Agent Hub brings agentic AI directly into these solutions, enabling more intelligent workflows and strengthening the high-stakes decisions that shape pricing, underwriting, customer engagement, growth, and profitability. In an increasingly turbulent insurance environment, the useful life of an insurance decision is getting shorter. Risk and market conditions are changing faster, making growth, profitability, and portfolio performance harder to manage. AI is increasing the speed and scope of what insurers can analyze, recommend, and increasingly act on — but as intelligence moves closer to action, the standard for governance, explainability, and accountability also rises. For insurers, that shift has direct implications for both financial per
Medisca Launches Global Peptide Division17.9.2026 16:07:00 EEST | Press release
Medisca today announced the launch of Medisca Peptides, a dedicated global division focused on expanding access to API-grade peptides and building an integrated peptide platform for pharmaceutical and personalized medicine markets worldwide. As the peptide landscape evolves, Medisca is proactively building the capabilities and infrastructure needed to support API-grade peptides within applicable regulatory frameworks. The launch represents a significant long-term commitment to peptides, including the expansion of Medisca’s portfolio, strategic manufacturing relationships, and the pharmaceutical infrastructure needed to support the category’s growth. It also signals Medisca’s ambition to become a leading force in the next generation of peptide innovation. For Medisca, the opportunity is familiar. More than 35 years ago, the company was founded to help close the gap between the pharmaceutical standards compounders needed and the quality ingredients they could readily access. Today, as pe
Elliptic Launches Its Decode Agent to Answer On-Chain Risk Questions and Shows Its Work17.9.2026 16:00:00 EEST | Press release
Elliptic, the global leader in on-chain risk, today launched Decode, an AI agent built on Elliptic’s intelligence platform. The Decode agent answers natural-language questions about cryptoasset addresses and their exposure in seconds, and returns the evidence behind every answer. Compliance and investigations teams need answers to questions nobody planned for. Getting them out of the data is now a specialist skill, so the questions wait for someone who has it, or go unasked. Meanwhile illicit actors move at machine speed, and agents are starting to sit on both sides of a payment. General-purpose AI assistants can produce an answer. They cannot show where it came from. A fluent response with nothing behind it cannot be put in front of a second-line reviewer, an auditor, or a regulator. “The market is full of AI that asks to be trusted. That is not good enough when someone asks how you reached a decision,” said Jackson Hull, CTO at Elliptic. “We published the Elliptic Standard last week
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
